{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:49:49Z","timestamp":1793386189424,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"crossref","award":["162300410308"],"award-info":[{"award-number":["162300410308"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an acute autoimmune neurological disorder mainly involving the peripheral nerves. Currently, various cytokines have been shown to be involved in the pathogenesis of GBS. Because of their similar biological structures, interleukin (IL)-36\u03b1, IL-36\u03b2, IL-36\u03b3, and IL-36 receptor antagonist (Ra) were all renamed and collectively called IL-36 cytokines. The roles of IL-36 cytokines in GBS currently remain unclear.<\/jats:p>\n            <jats:p>Forty-two patients with GBS and 32 healthy volunteers were included in our study. Serum IL-36\u03b1, \u03b2, \u03b3, and interleukin-36 receptor antagonist (IL-36Ra) levels of patients with GBS in the acute and remission phases and healthy volunteers were measured by enzyme-linked immunosorbent assay (ELISA). In addition, we examined the serum levels of other inflammatory factors that have been shown to be involved in GBS pathogenesis, represented by IL-17 and tumor necrosis factor-\u03b1 (TNF-\u03b1). Furthermore, the correlations between the serum levels of IL-36 cytokines and different clinical data or the serum levels of other inflammatory factors in GBS patients were analyzed.<\/jats:p>\n            <jats:p>Significantly higher serum IL-36\u03b1 and IL-36\u03b3 levels were measured in the acute phase than in the remission phase and in healthy control (HC) subjects (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05), while lower serum IL-36Ra levels were measured in the acute phase than in the remission phase and in HC subjects (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05). Serum IL-36\u03b1 and IL-36\u03b3 levels were positively correlated with GBS disability scale scores (GDSs), while serum IL-36Ra levels were negatively correlated with GDSs. Correlation analyses among inflammatory factors showed that serum IL-36\u03b1 and IL-36\u03b3 levels in GBS patients were positively correlated with serum IL-17 and TNF-\u03b1 levels, while serum IL-36Ra levels were negatively correlated with the levels of these 2 inflammatory factors. Similar results were observed in cerebrospinal fluid (CSF), IL-36\u03b1 and IL-36\u03b3 levels in CSF were positively correlated with GDSs, while IL-36Ra levels in CSF were negatively correlated with GDSs. Additionally, the serum and CSF levels of IL-36\u03b1 and IL-36\u03b3 in the axonal subtype of GBS patients were higher than those in the demyelination subtype.<\/jats:p>\n            <jats:p>Based on our findings, IL-36 cytokines may be involved in the pathogenesis of GBS and some of these cytokines may help predict the disease severity and other clinical characteristics of GBS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023832","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T10:00:56Z","timestamp":1608631256000},"page":"e23832","source":"Crossref","is-referenced-by-count":3,"title":["Altered serum levels of IL-36 cytokines (IL-36\u03b1, IL-36\u03b2, IL-36\u03b3, and IL-36Ra) and their potential roles in Guillain-Barr\u00e9 syndrome"],"prefix":"10.1097","volume":"99","author":[{"given":"Zhikang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Emergency"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Emergency"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neurol.2016.08.006","article-title":"Guillain-Barr\u00e9 syndrome: what have we learnt during one century? A personal historical perspective","volume":"172","author":"Uncini","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.autrev.2014.01.033","article-title":"Guillain Barr\u00e9 syndrome and other immune mediated neuropathies: diagnosis and classification","volume":"13","author":"Eldar","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1474-4422(13)70215-1","article-title":"Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara","year":"2013","journal-title":"Lancet Neurol"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2018.01.006","article-title":"Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barr\u00e9 syndrome","volume":"317","author":"Loshaj-Shala","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"e0007695","DOI":"10.1371\/journal.pntd.0007695","article-title":"Anti-ganglioside antibodies in patients with Zika virus infection-associated Guillain-Barr\u00e9 Syndrome in Brazil","volume":"13","author":"Rivera-Correa","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2009.10.018","article-title":"Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barr\u00e9 syndrome in Northern Indian population","volume":"218","author":"Nyati","year":"2010","journal-title":"J Neuroimmunol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","article-title":"Guillain-Barr\u00e9 syndrome: a century of progress","volume":"12","author":"Goodfellow","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00415-010-5836-5","article-title":"The role of cytokines in Guillain-Barr\u00e9 syndrome","volume":"258","author":"Lu","year":"2011","journal-title":"J Neurol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"260473","DOI":"10.1155\/2012\/260473","article-title":"IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barr\u00e9 syndrome","volume":"2012","author":"Li","year":"2012","journal-title":"Mediators Inflamm"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol Rev"},{"key":"R13-20230915","first-page":"1649","article-title":"Interleukin-36: structure, signaling and function","volume":"20","author":"Zhou","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/nyas.13280","article-title":"The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases","volume":"1417","author":"Walsh","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J Biol Chem"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.1400538","article-title":"Molecular determinants of agonist and antagonist signaling through the IL-36 receptor","volume":"193","author":"G\u00fcnther","year":"2014","journal-title":"J Immunol: official journal of the American Association of Immunologists"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.smim.2013.11.003","article-title":"Biology of IL-36 cytokines and their role in disease","volume":"25","author":"Gresnigt","year":"2013","journal-title":"Semin Immunol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/eji.201646788","article-title":"Interleukin-36 receptor mediates the crosstalk between plasma cells and synovial fibroblasts","volume":"47","author":"Schmitt","year":"2017","journal-title":"Eur J Immunol"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41584-019-0277-8","article-title":"The IL-1 family of cytokines and receptors in rheumatic diseases","volume":"15","author":"Dinarello","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R20-20230915","first-page":"20","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"106341","DOI":"10.1016\/j.intimp.2020.106341","article-title":"Profile of IL-36 cytokines (IL-36\u03b1, IL-36\u03b2, IL-36\u03b3 and IL-36Ra) in patients with primary immune thrombocytopenia","volume":"82","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-018-21025-5","article-title":"IL-23 and IL-27 levels in serum are associated with the process and the recovery of Guillain-Barr\u00e9 syndrome","volume":"8","author":"Peng","year":"2018","journal-title":"Sci Rep"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcell.2019.00317","article-title":"Function and regulation of IL-36 signaling in inflammatory diseases and cancer development","volume":"7","author":"Queen","year":"2019","journal-title":"Front cell Dev Biol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/eji.201242711","article-title":"The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses","volume":"43","author":"Gresnigt","year":"2013","journal-title":"Eur J Immunol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/eji.201142035","article-title":"Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9","volume":"42","author":"Mutamba","year":"2012","journal-title":"Eur J Immunol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1172\/JCI63451","article-title":"Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk","volume":"122","author":"Tortola","year":"2012","journal-title":"J Clin Invest"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cellimm.2018.04.011","article-title":"Class I PI3K inhibitor ZSTK474 attenuates experimental autoimmune neuritis by decreasing the frequency of Th1\/Th17 cells and reducing the production of proinflammatory cytokines","volume":"329","author":"Chen","year":"2018","journal-title":"Cell Immunol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12974-016-0559-x","article-title":"Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2\/hemoxygenase-1 pathway by altering the balance of M1\/M2 macrophages","volume":"13","author":"Han","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2340\/00015555-2808","article-title":"Highlighting interleukin-36 signalling in plaque psoriasis and pustular psoriasis","volume":"98","author":"Furue","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"8980534","DOI":"10.1155\/2017\/8980534","article-title":"Correlation between IL36\u03b1 and IL17 and activity of the disease in selected autoimmune blistering diseases","volume":"2017","author":"\u017bebrowska","year":"2017","journal-title":"Mediators Inflamm"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3349\/ymj.2006.47.5.729","article-title":"Inflammatory gene expression patterns revealed by DNA microarray analysis in TNF-alpha-treated SGBS human adipocytes","volume":"47","author":"Do","year":"2006","journal-title":"Yonsei Med J"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/ijms20071649","article-title":"IL-36 cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction","volume":"20","author":"Murrieta-Coxca","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.3389\/fimmu.2019.01162","article-title":"Interleukin-36 in infectious and inflammatory skin diseases","volume":"10","author":"Buhl","year":"2019","journal-title":"Front Immunol"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"R37-20230915","doi-asserted-by":"crossref","first-page":"19588","DOI":"10.3390\/molecules201019588","article-title":"Elevated expression and pro-inflammatory activity of IL-36 in patients with systemic lupus erythematosus","volume":"20","author":"Chu","year":"2015","journal-title":"Molecules"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4103\/neuroindia.NI_1226_15","article-title":"Anti-ganglioside antibodies profile in Guillain-Barr\u00e9 syndrome: correlation with clinical features, electrophysiological pattern, and outcome","volume":"65","author":"Naik","year":"2017","journal-title":"Neurol India"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.03.019","article-title":"Increased plasmacytoid dendritic cells in Guillain-Barr\u00e9 syndrome","volume":"283","author":"Wang","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1128\/IAI.69.4.2462-2469.2001","article-title":"Guillain-Barr\u00e9 syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b antibodies in rabbits","volume":"69","author":"Ang","year":"2001","journal-title":"Infect Immun"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:43:28Z","timestamp":1694828608000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":42,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023832","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,24]]}}}